Immunotherapy Combination Shown to Benefit Some Patients with Non–Small Cell Lung Cancer Resistant to Single Immunotherapy
February 7th 2022
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non–small cell lung cancer that was resistant to a single immunotherapy agent.